Fig. 3From: Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab eraOS and PFS stratified by number of residual diseases at the time of RT. OS (A) and PFS (B) were worse when patients had multiple residual diseaseBack to article page